$ADMA

Grossman Jerrold B purchased $51K of ADMA

Grossman Jerrold B purchased 6,400 shares of ADMA BIOLOGICS, INC. (ADMA) at $7.91 on 2026-05-27.

Original reporting
SEC EDGAR · Grossman Jerrold B
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ADMA
Bullish
medium confidence
Mentioned
$ADMA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADMABullishLow
01

Why it matters

The disclosure updates insider ownership and can slightly influence sentiment, but it does not provide new guidance, trial results, contracts, or regulatory actions.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it still provides no context on motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: Form 4 filed May 28, 2026 for a May 27 purchase

Background

The article is a SEC Form 4 insider transaction disclosure for ADMA BIOLOGICS, Inc.

Company-level read

Ticker impact

$ADMABullishMedium confidence
Context

ADMA BIOLOGICS director Grossman Jerrold B bought 6,400 shares at $7.91 in a Form 4 filed May 28, 2026.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4 and is company-specific, but it does not include new operational, financial, or regulatory information beyond the transaction details.

Market effects

No clear sector read-through from a single director open-market purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • ADMA BIOLOGICS, INC.

    Company whose director insider purchase is disclosed on Form 4.

  • Grossman Jerrold B

    Director who purchased 6,400 shares at $7.91 on May 27, 2026.

Related articles

$ADMAHigh

ADMA BIOLOGICS, INC. (ADMA): Results of Operations and Financial Condition

ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079311_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year

$ADMAMed

ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors

ADMA Biologics (NASDAQ:ADMA) faces a securities fraud class action after its shares fell about 29%, following Culper Research allegations of channel stuffing tied to reported 20% 2025 growth. The complaint cites potential violations of Sections 10(b) and 20(a). ADMA stock dropped from $13.59 (Mar 23, 2026) to $9.63 (Mar 25) after the report.

$ADMAMed

ADMA Class Reminder: ADMA Biologics Investors are Reminded of the Upcoming August 10 Deadline in the Filed Securities Fraud Class Action to Recover Losses

Bleichmar Fonti & Auld LLP said a securities fraud class action was filed against ADMA Biologics (NASDAQ:ADMA) and executives, alleging federal securities law violations tied to Culper Research claims of channel stuffing. The suit cites a March 24, 2026 16.6% drop after a report alleging undisclosed related-party distributor activity. Investors have until Aug. 10, 2026 to seek lead-plaintiff status.

$ADMAMed

ADMA Lawsuit Notice: ADMA Biologics Channel Stuffing Allegations and 29% Stock Drop Trigger Securities Fraud Class Action

Bleichmar Fonti & Auld LLP says it filed a securities fraud class action against ADMA Biologics (NASDAQ:ADMA) and executives after ADMA shares fell about 29% following Culper Research’s channel-stuffing allegations tied to reported 20% 2025 growth and ASCENIV. The complaint cites Sections 10(b) and 20(a) and names Mazzarino v. ADMA Biologics, No. 26-cv-6918, with an Aug. 10, 2026 lead-plaintiff deadline.

$ADMAMedAI 8/10

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against ADMA Biologics (NASDAQ: ADMA)

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against ADMA Biologics (NASDAQ: ADMA) in the District of New Jersey for purchases between Aug. 9, 2024 and Mar. 25, 2026. Allegations include undisclosed related-party transactions, channel stuffing, and weak internal controls. The firm cites a March 24 Culper Research report tied to a 29.1% stock drop on Mar. 25. Lead plaintiff deadline: Aug. 10, 2026.

$ADMAMedAI 8/10

ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV

The article claims ADMA Biologics received an FDA label expansion for its ASCENIV product, but it provides no additional details or figures. The rest is promotional content for an “Insider Monkey” newsletter, citing broad AI/robotics themes and alleging a prior stock call (British American Tobacco) returned 90% in 16 months.